Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6601787.pdf
Reference38 articles.
1. Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Piroetti E (1999) Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and resistant ovarian cancer. Gynecol Oncol 72: 60–64
2. Cannistra S (2002) Is there a ‘best’ choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20: 1158–1160
3. Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V Colombo N (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20: 1232–1237
4. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II and long-term follow-up of patients treated with Paclitaxel for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748–1753
5. Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors response to subsequent chemotherapy in platinum pre-treated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963–968
Cited by 75 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical and molecular features of platinum resistance in ovarian cancer;Critical Reviews in Oncology/Hematology;2024-09
2. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer;Cancers;2024-07-15
3. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials;BMC Women's Health;2024-01-13
4. Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT);Journal of Gynecologic Oncology;2024
5. Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression;OncoImmunology;2023-04-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3